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Orderly passage through the cell cycle is
controlled by the well-timed appearance
and disappearance of numerous regula-
tory proteins, most notably the cyclins
and their inhibitors. One of the major
forces driving the cell cycle is ubiquitin
(Ub)-mediated proteolysis, a process in
which covalent attachment of Ub to tar-
get proteins signals their destruction by
the 26S proteasome. Specificity in prote-
olysis by the Ub-proteasome system is
governed largely by the action of Ub-pro-
tein ligases (Ubls), multisubunit complex-
es that recognize “degrons” in substrate
proteins and bring them face-to-face with
core components of the ubiquitylation
machinery.Two families of Ubls dominate
cell duplication and division—SCF and
APC—and until now these families have
been thought to act independently as
“waves of destruction” that regulate dis-
crete phases in the cell cycle (Figure 1).
The SCF (Skp-Cullin-F box) family
of Ubls consist of a number of core com-
ponents—Skp1, Cul1, Roc1—
in complex with a unique “F
box” protein that confers sub-
strate specificity. F box pro-
teins have at least two
functional domains—an ?40
amino acid F box domain that
binds Skp1 and tethers the F
box protein to the core SCF
components, and a protein-
protein interaction domain
(often a series of leucine-rich
repeats or WD40 domains)
that specifically binds sub-
strate proteins. A vast collec-
tion of F box proteins, each
with different substrate speci-
ficity, exists in mammals, with
proteins such as β-TrCP,
hCDC4, and Skp2 being the
best characterized (reviewed
in Spruck and Strohmaier,
2002).
SCF-type Ubls have been
show to regulate a variety of dif-
ferent processes from transcription
through to development. Perhaps their
most prominent role, however, is control of
the G1/S transition of the cell cycle. Skp2-
containing SCF complexes (SCFSkp2), in
particular, are fundamental to this transi-
tion, targeting the destruction of numer-
ous regulatory proteins—including p27,
p21, and p130—that inhibit S phase
entry (reviewed in Reed, 2003). By
destroying these S phase inhibitors,
SCFSkp2 thus removes the S phase block,
allowing DNA replication to proceed.
Given its central role in the G1/S transi-
tion, it is not surprising that Skp2
behaves like an oncogene. Forced
expression of Skp2 drives cellular trans-
formation both in vitro and in vivo, and
several human cancers, including carci-
nomas and lymphomas, display elevated
Skp2 protein levels (Gstaiger et al.,
2001). Increased expression of Skp2 in
cancer patients correlates with reduced
levels of the SCFSkp2 target protein p27,
which in turn is an indicator of poor prog-
nosis in such cancers (reviewed in
Bloom and Pagano, 2003).
Like SCF, the APC, or anaphase-pro-
moting complex, is a multisubunit Ubl
that consists of a number of core compo-
nents in complex with a unique substrate
specificity factor. For APC, however, the
math is a little different; there are 13 core
components, but just two specificity fac-
tors—Cdc20 and Cdh1 (Reed, 2003). As
its name implies, APC is intimately asso-
ciated with mitosis, and Cdc20 and Cdh1
play distinct roles in various phases of
cell division. Cdc20 is synthesized late in
G2 and coordinates events required for
the onset of mitosis through to
anaphase. Cdh1, on the other hand,
becomes active toward the end of
anaphase and ultimately brings about
the end of mitosis by targeting destruc-
tion of Cdc20, as well as mitotic cyclins
and other regulators.
Unlike SCFSkp2, there have been only
a few reports linking APC to
cancer. Genetic alterations
in two subunits of the APC,
CDC16 and CDC23, are
found in some colon cancer
cells (Wang et al., 2003).
And recently it has been
suggested that RASSF1A,
a tumor suppressor that is
frequently silenced in can-
cers, can act as an inhibitor
of Cdc20, thus preventing
mitotic progression due to
premature APC activation
(Song et al., 2004).
Although it has been
satisfying to think of SCF
and APC as two indepen-
dent machines that drive
distinct phases of the cell
cycle, this view will now
have to change. Two papers
published in the March 11
issue of Nature (Bashir et
al., 2004; Wei et al., 2004)
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Figure 1. Waves of destruction
SCF and APC ubiquitin-ligases are important regulators of cell cycle
transitions. As such, the cell cycle has been described as being driven
by waves of Ub-dependent protein degradation (Wei et al., 2004).
By destroying specific substrates, APC-type ligases regulate entry into
and exit from mitosis, whereas SCFSkp2 controls entry into S phase. A
subset of cell-cycle regulatory substrates for each Ubl is listed. Note
that by targeting the SCF-component Skp2 for destruction, APCCdh1
not only regulates exit from mitosis, but also controls the duration of
G1. Because of the central role of Skp2 in timing the onset of S phase,
loss of Skp2 regulation by APCCdh1 could result in ectopic S phase entry
and in the development of cancer.
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blur the demarcation between SCF and
APC by demonstrating that APCCdh1 tar-
gets destruction of Skp2 during the G1
phase of the cell cycle. This work is
important because it challenges the
compartmentalized view of Ubls and the
cell cycle, and because it identifies a Ubl
for a major G1/S regulator and oncopro-
tein, Skp2. Critically, however, the work is
also profound because it establishes
APCCdh1 as a major G1 regulator, control-
ling both entry into G1—by destruction of
Cdc20 and mitotic cyclins—and, now,
the duration of G1—by destruction of
Skp2.
The experiments performed by each
group were similar in approach and
scope. During an investigation of cell
cycle changes in Skp2 protein expres-
sion, Bashir et al. found that Skp2 is
downregulated in late M and G1, and
induced only as cells near S phase. This
expression pattern correlated with pro-
tein half-life, with Skp2 turning over more
rapidly in cells in late M/early G1 than
those in prometaphase. Wei et al. provid-
ed similar data, demonstrating that
lysates prepared from cells synchro-
nized in G1 support rapid turnover of
Skp2, whereas lysates prepared from
cells synchronized in S phase did not.
Both groups noted the similarity of Skp2
expression patterns to that of the mitotic
cylins and demonstrated that Skp2 con-
tains a functional “D box,” one of two
degrons recognized by the APC (Reed,
2003). Importantly, both groups provide
strong and compelling data that APCCdh1
is indeed a Ub-protein ligase for Skp2;
together, their experiments show that
forced expression of Cdh1 promotes
Skp2 proteolysis, that attenuating Cdh1
expression by siRNA stabilizes Skp2,
that Skp2 and Cdh1 physically interact,
and that immunopurified APCCdh1 can
polyubiquitylate Skp2 in vitro.
Perhaps the most striking feature of
all this destruction is the effect of the
APC-SCF interaction on cell cycle con-
trol. Forms of Skp2 that are refractory to
APCCdh1-mediated destruction promoted
a premature entry into S phase.
Suppression of Cdh1 by siRNA (which in
turn promotes accumulation of Skp2)
increased the rate of p27 degradation
and dramatically accelerated S phase
entry. Amazingly, the ability of Cdh1
knockdown to stimulate the onset of
DNA replication was entirely dependent
on Skp2, revealing that Skp2 is an
essential target through which APCCdh1
regulates the timing of the G1/S transi-
tion. These data firmly establish that
APCCdh1 antagonizes SCFSkp2 action dur-
ing G1, and demonstrate convincingly
that APC isn’t just a regulator of mitosis
anymore.
What is the relevance of this mode of
regulation to cancer? Given that APCCdh1
targets Skp2 for destruction, and that
Skp2 itself is very likely to be the product
of an oncogene, it is tempting to specu-
late that Cdh1 may function as a tumor
suppressor. As mentioned, evidence
suggesting that Cdh1, or indeed any
APC subunit, is dysregulated in cancer is
scanty. One possible explanation is that
APC is a central cog in the cell cycle
machinery, and that it is difficult for can-
cer to select for mutations that acceler-
ate the rate of cell proliferation without
simply causing the entire cell cycle to
crash. But it is also possible that we sim-
ply haven’t been looking in the right
place. Skp2 is overexpressed in some
cancers, and although the mechanism is
often attributed to gene amplification
(Dowen et al., 2003), it seems plausible
that stabilization of Skp2 could also be a
mechanism of Skp2 activation in cancer.
Based on the Bashir et al. and Wei et al.
studies, we might predict that Cdh1 itself
is disrupted in human malignancy, or at
the very least that the APCCdh1-Skp2 D
box interaction is targeted by some can-
cer-relevant process. Thus, in addition to
providing food for thought about how Ub-
ligases can stretch their influence
throughout the cell cycle, the reports by
Bashir et al. and Wei et al. might just
have given us the heads up on an
unexpected mechanism targeted during
oncogenesis.
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